Correlation Between American Airlines and Eupraxia Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both American Airlines and Eupraxia Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining American Airlines and Eupraxia Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between American Airlines Group and Eupraxia Pharmaceuticals Common, you can compare the effects of market volatilities on American Airlines and Eupraxia Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in American Airlines with a short position of Eupraxia Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of American Airlines and Eupraxia Pharmaceuticals.

Diversification Opportunities for American Airlines and Eupraxia Pharmaceuticals

0.68
  Correlation Coefficient

Poor diversification

The 3 months correlation between American and Eupraxia is 0.68. Overlapping area represents the amount of risk that can be diversified away by holding American Airlines Group and Eupraxia Pharmaceuticals Commo in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eupraxia Pharmaceuticals and American Airlines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on American Airlines Group are associated (or correlated) with Eupraxia Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eupraxia Pharmaceuticals has no effect on the direction of American Airlines i.e., American Airlines and Eupraxia Pharmaceuticals go up and down completely randomly.

Pair Corralation between American Airlines and Eupraxia Pharmaceuticals

Considering the 90-day investment horizon American Airlines Group is expected to generate 0.52 times more return on investment than Eupraxia Pharmaceuticals. However, American Airlines Group is 1.91 times less risky than Eupraxia Pharmaceuticals. It trades about 0.21 of its potential returns per unit of risk. Eupraxia Pharmaceuticals Common is currently generating about 0.1 per unit of risk. If you would invest  1,283  in American Airlines Group on September 23, 2024 and sell it today you would earn a total of  405.00  from holding American Airlines Group or generate 31.57% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

American Airlines Group  vs.  Eupraxia Pharmaceuticals Commo

 Performance 
       Timeline  
American Airlines 

Risk-Adjusted Performance

17 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in American Airlines Group are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Despite quite abnormal basic indicators, American Airlines disclosed solid returns over the last few months and may actually be approaching a breakup point.
Eupraxia Pharmaceuticals 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Eupraxia Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

American Airlines and Eupraxia Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with American Airlines and Eupraxia Pharmaceuticals

The main advantage of trading using opposite American Airlines and Eupraxia Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if American Airlines position performs unexpectedly, Eupraxia Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will offset losses from the drop in Eupraxia Pharmaceuticals' long position.
The idea behind American Airlines Group and Eupraxia Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Complementary Tools

Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Global Correlations
Find global opportunities by holding instruments from different markets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Transaction History
View history of all your transactions and understand their impact on performance